• Antiemetic therapy of early toxicity in pregnant women with congenital heart disease 

Antiemetic therapy of early toxicity in pregnant women with congenital heart disease 

PERINATOLOGIYA I PEDIATRIYA. 2016.3(67):35-37; doi 10.15574/PP.2016.67.35 
 

Antiemetic therapy of early toxicity in pregnant women with congenital heart disease 
 

Davydova I. V., Limanskaya A. Yu., Butenko L. P., Ogorodnik A. A.

SI «Institute of Pediatrics, Obstetrics and Gynecology NAMS of Ukraine», Kiev 
 

Objective — to study the effectiveness of the Yunorm (Yuria-Farm) in the treatment of early severe toxicity in pregnant women with cardiovascular disease and anemia.


Patients and methods. We examined 28 women with congenital heart disease and anemia who had received Yunorm (Yuria-Farm) intravenously by 2 ml (4 mg of ondansetron) per day (in severe cases twice a day) for the relief of emesis and nausea as a manifestation of moderate and severe early toxicity in pregnant women.


Results. The high efficiency and safety of Yunorm (ondansetron) preparation, which was administrated intravenously for the treatment of nausea and vomiting during pregnancy is found. The safety of the use during gestation period was confirmed by the absence of significant side effects in women, significant changes in the fetus state and newborn.


Conclusions. According to its safety profile ondansetron is qualified as B according to the FDA classification and can be recommended as an effective and safe anti-emetic preparation for use in obstetric practice.


Key words: toxemia of pregnancy, cardiovascular disease, anemia, antiemetic therapy.


REFERENCES

1. Mayhall EA, Gray R, Lopes V, Matteson KA 2015. Comparison of antiemetics for nausea and vomiting of pregnancy in an emergency department setting. Am J Emerg Med. 33: 882—886. http://dx.doi.org/10.1016/j.ajem.2015.03.032; PMid:25921968

2. Danielsson B, Wikner BN, Kallen B, Danielsson B. 2014. Use of ondansetron during pregnancy and congenital malformations in the infant. Reprod Toxicol. 50: 134—137. http://dx.doi.org/10.1016/j.reprotox.2014.10.017; PMid:25450422

3. Ebrahimi N, Maltepe C, Einarson A. 2010. Optimal management of nausea and vomiting of pregnancy. Int J Womens Health. 2: 241—248. http://dx.doi.org/10.2147/IJWH.S6794; PMid:21151729 PMCid:PMC2990891

4. Lee NM, Saha S. 2011. Nausea and vomiting of pregnancy. Gastroenterol Clin North Am. 40: 309—334. http://dx.doi.org/10.1016/j.gtc.2011.03.009; PMid:21601782 PMCid:PMC3676933

5. Mitchell AA, Gilboa SM, Werler MM et al. 2011. National Birth Defects Prevention Study. Medication use during pregnancy, with particular focus on prescription drugs: 1976—2008. Am J Obstet Gynecol. 205: 51.e1—8. http://dx.doi.org/10.1016/j.ajog.2011.02.029; PMid:21514558 PMCid:PMC3793635

6. Anderka M, Mitchell AA, Louik C et al. 2012. National Birth Defects Prevention Study. Medications used to treat nausea and vomiting of pregnancy and risk of selected birth defects. Birth Defects Res A Clin Mol Teratol. 94: 22—30. http://dx.doi.org/10.1002/bdra.22865; PMid:22102545 PMCid:PMC3299087

7. Nausea and vomiting of pregnancy: Educational Series on Women's Health. American Professors in Gynecology and Obstetrics. 2015.

8. Pasternak B, Svanstrom H, Hviid A. 2013. Ondansetron in pregnancy and risk of adverse fetal outcomes. N Engl J Med. 368: 814—823. http://dx.doi.org/10.1056/NEJMoa1211035; PMid:23445092

9. Practice Bulletin: nausea and vomiting of pregnancy. American College of Obstetricians and Gynecologist. Obstet Gynecol. 2004. 103: 803—814. http://dx.doi.org/10.1097/00006250-200404000-00045; PMid:15051578

10. Einarson A, Maltepe C, Navioz Y et al. 2004. The safety of ondansetron for nausea and vomiting of pregnancy: A prospective comparative study. BJOG. 111: 940—943. http://dx.doi.org/10.1111/j.1471-0528.2004.00236.x; PMid:15327608